[go: up one dir, main page]

MX2018007721A - Cocristal, metodo de produccion del mismo, y medicamento que contiene el cocristal. - Google Patents

Cocristal, metodo de produccion del mismo, y medicamento que contiene el cocristal.

Info

Publication number
MX2018007721A
MX2018007721A MX2018007721A MX2018007721A MX2018007721A MX 2018007721 A MX2018007721 A MX 2018007721A MX 2018007721 A MX2018007721 A MX 2018007721A MX 2018007721 A MX2018007721 A MX 2018007721A MX 2018007721 A MX2018007721 A MX 2018007721A
Authority
MX
Mexico
Prior art keywords
crystal
acid
same
production method
product contained
Prior art date
Application number
MX2018007721A
Other languages
English (en)
Other versions
MX380656B (es
Inventor
Sawai Yasuhiro
Kimoto Koya
Yamamoto Mitsuo
Iwata Kentaro
Kitayama Masato
Hohokabe Miyuki
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2018007721A publication Critical patent/MX2018007721A/es
Publication of MX380656B publication Critical patent/MX380656B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/08Malonic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/145Maleic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265Citric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/42Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/48Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
    • C07C59/50Mandelic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/42Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/54Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C07C65/10Salicylic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención proporciona un cocristal de (S)-3-(1-((1-acriloilpirrolidin-3-il)oxi)isoquinolin-3-il)-1H-1,2 ,4-triazol-5(4H)-ona y un ácido orgánico capaz de formar un cocristal con el compuesto. Los cocristales específicos preparados son cocristales con ácido gentísico, ácido salicílico, ácido maleico, ácido malónico, ácido málico, ácido mandélico o ácido cítrico.
MX2018007721A 2015-12-24 2016-12-22 Cocristal, metodo de produccion del mismo, y medicamento que contiene el cocristal. MX380656B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015252658 2015-12-24
PCT/JP2016/089224 WO2017111179A1 (en) 2015-12-24 2016-12-22 Cocrystal, production method thereof, and medicament containing cocrystal

Publications (2)

Publication Number Publication Date
MX2018007721A true MX2018007721A (es) 2018-08-15
MX380656B MX380656B (es) 2025-03-12

Family

ID=57910088

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007721A MX380656B (es) 2015-12-24 2016-12-22 Cocristal, metodo de produccion del mismo, y medicamento que contiene el cocristal.

Country Status (25)

Country Link
US (1) US10836745B2 (es)
EP (1) EP3394045B1 (es)
JP (1) JP6876704B2 (es)
KR (1) KR102687603B1 (es)
CN (1) CN108473467B (es)
AR (1) AR107132A1 (es)
AU (1) AU2016375899B2 (es)
CA (1) CA3009610C (es)
CL (1) CL2018001725A1 (es)
CO (1) CO2018006473A2 (es)
DK (1) DK3394045T3 (es)
EA (1) EA039213B1 (es)
EC (1) ECSP18055921A (es)
ES (1) ES2877089T3 (es)
HK (1) HK1256362A1 (es)
IL (1) IL260195A (es)
MX (1) MX380656B (es)
PH (1) PH12018501356A1 (es)
PL (1) PL3394045T3 (es)
SG (1) SG11201805331QA (es)
TN (1) TN2018000221A1 (es)
TW (1) TWI722080B (es)
UY (1) UY37046A (es)
WO (1) WO2017111179A1 (es)
ZA (1) ZA201804393B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY207190A (en) 2017-10-06 2025-02-05 Cargill Inc Readily dissolvable steviol glycoside compositions
CA3078200C (en) * 2017-10-06 2023-09-19 Cargill, Incorporated Steviol glycoside solubility enhancers
CA3135185A1 (en) 2019-04-06 2020-10-15 Cargill, Incorporated Sensory modifiers
CN110818692B (zh) * 2019-11-08 2023-03-24 中国海洋大学 一种替加氟与丁香酸的共晶及其制备方法
TWI845802B (zh) * 2020-04-21 2024-06-21 健亞生物科技股份有限公司 硫酸羥氯喹之晶體
CN117383998A (zh) * 2023-09-28 2024-01-12 天津理工大学 一种共晶的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
BR9812866A (pt) 1997-10-07 2000-08-08 Schering Corp Polimorfo antifúngico cristalino
US6608055B2 (en) 2001-06-22 2003-08-19 Boehringer Ingelheim Pharma Kg Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition
US6737432B2 (en) 2001-10-31 2004-05-18 Boehringer Ingelheim Pharma Kg Crystalline form of telmisartan sodium
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
WO2008105195A1 (ja) 2007-02-28 2008-09-04 Nsk Ltd. チルト式ステアリング装置
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
RU2012126029A (ru) 2009-12-03 2014-01-10 Астразенека Аб Сокристаллы триазоло[4,5 d]пиримидинового ингибитора агрегации тромбоцитов
CA2841080A1 (en) 2011-07-13 2013-01-17 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج

Also Published As

Publication number Publication date
IL260195A (en) 2018-07-31
KR102687603B1 (ko) 2024-07-24
DK3394045T3 (da) 2021-08-16
HK1256362A1 (zh) 2019-09-20
PH12018501356A1 (en) 2019-02-18
EA039213B1 (ru) 2021-12-17
EP3394045A1 (en) 2018-10-31
US20170183326A1 (en) 2017-06-29
CN108473467B (zh) 2021-08-13
CA3009610C (en) 2024-02-13
UY37046A (es) 2017-07-31
EP3394045B1 (en) 2021-05-19
SG11201805331QA (en) 2018-07-30
CO2018006473A2 (es) 2018-07-10
ECSP18055921A (es) 2018-10-31
CA3009610A1 (en) 2017-06-29
BR112018012915A2 (pt) 2018-12-11
KR20180095933A (ko) 2018-08-28
PL3394045T3 (pl) 2021-09-27
US10836745B2 (en) 2020-11-17
WO2017111179A1 (en) 2017-06-29
CN108473467A (zh) 2018-08-31
AU2016375899A1 (en) 2018-07-19
ZA201804393B (en) 2019-09-25
JP6876704B2 (ja) 2021-05-26
EA201891467A1 (ru) 2018-12-28
AU2016375899B2 (en) 2021-05-13
ES2877089T3 (es) 2021-11-16
JP2019504025A (ja) 2019-02-14
AR107132A1 (es) 2018-03-21
TWI722080B (zh) 2021-03-21
TW201730181A (zh) 2017-09-01
TN2018000221A1 (en) 2019-10-04
CL2018001725A1 (es) 2018-10-19
MX380656B (es) 2025-03-12

Similar Documents

Publication Publication Date Title
MX2018007721A (es) Cocristal, metodo de produccion del mismo, y medicamento que contiene el cocristal.
DOP2022000172A (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd)
GT201500348A (es) Compuestos de pirimidinodiona contra estados cardíacos
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
MX375707B (es) Compuesto derivativo triciclico, metodo para prepararlo y composicion farmaceutica que comprende el mismo.
ECSP17005635A (es) Inhibidores de desmetilasa-1 específica a lisina
MA49287A (fr) Nouvelle immunothérapie contre plusieurs tumeurs du sang, tels que la leucémie myéloïde aiguë (aml)
MX2016010266A (es) Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso.
DOP2019000193A (es) Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende
ECSP18024565A (es) Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas
CL2017000368A1 (es) Compuestos fusionados de 11 miembros y fungicidas agrícolas/hortícolas que los contienen
CR20170092A (es) Compuestos y composiciones como inhibidores de quinasa raf
CO2017010806A2 (es) Método para manufacturar compuesto novedoso que contiene nitrógeno o sal del mismo e intermediario de manufacturación del compuesto novedoso que contiene nitrógeno o sal del mismo
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
ZA201707152B (en) Methods for hydraulic enhancement of crops
CO2018007008A2 (es) "procesos mejorados para la preparación de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo"
MX2017007840A (es) Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo.
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
DOP2019000194A (es) Derivados de pirrolotriazina como inhibidor de cinasas
MX390841B (es) Preparacion liquida parenteral que comprende compuesto de carbamato.
AR107163A1 (es) Inhibidores de quinasa
CL2019000294A1 (es) Síntesis de (s)-2-amino-4-metil-1-((r)-2-metiloxirano-2-il)-pentan-1-ona y sales farmacéuticamente aceptables de la misma.
CO2019010117A2 (es) Proceso para la separación de isómeros ópticos de etilésteres racémicos del ácido 3-alquilpiperidin-carboxílico
TR201902863T4 (tr) Eri̇tropoi̇eti̇n ve seftri̇akson i̇çeren farmasöti̇k bi̇r bi̇leşi̇m ve parki̇nson hastaliği demansinin tedavi̇si̇ i̇çi̇n bi̇r i̇lacin üreti̇lmesi̇nde bunun bi̇r kullanimi.
FR3024823B1 (fr) Semelle ventilee d'article chaussant et son procede de fabrication, et article chaussant obtenu integrant une telle semelle